Benz, Kerstin and Orth, Stephan R. and Simonaviciene, Aurelia and Linz, Wolfgang and Schindler, Ursula and Ruetten, Hartmut and Amann, Kerstin (2007) Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. KIDNEY & BLOOD PRESSURE RESEARCH, 30 (4). pp. 224-233. ISSN 1420-4096, 1423-0143
Full text not available from this repository. (Request a copy)Abstract
Nitric oxide formation is impaired in chronic renal failure. The renoprotective effects of a nonhypotensive dose of HMR1766, a direct activator of the heme enzyme soluble guanylyl cyclase was studied in comparison to an ACE- i in the remnant kidney model. Male Sprague- Dawley rats were subtotally nephrectomized ( SNX) or sham operated ( sham) and left untreated or started on treatment with HMR1766 or ACE- i in non- hypotensive doses. BP, albumin excretion and parameters of renal damage were analyzed. After a 12- week study, urinary albumin excretion was significantly higher in untreated SNX than in sham; this increase was prevented by ACE- i and ameliorated by HMR1766. Relative kidney and left ventricular weight were significantly higher in untreated SNX compared to sham; these changes were completely prevented by HMR1766. In untreated SNX, glomerulosclerosis ( 1.02 +/- 0.13) was significantly higher than in sham ( 0.12 +/- 0.04), SNX+ HMR1766 ( 0.27 +/- 0.04) and SNX+ ACE- i ( 0.46 +/- 0.06). Tubulointerstitial changes went in parallel. Increased glomerular cell number after SNX ( 71.5 +/- 14 vs. 60 8 7.3 in sham) was prevented by HMR1766 ( 55.7 +/- 7.3), but not by ACE- i ( 66.6 +/- 9). The results document beneficial BP- independent HMR1766 effects on kidney structure and urinary albumin excretion in a noninflammatory model of renal failure and may argue for a novel therapeutic principle.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NITRIC-OXIDE; VENTRICULAR HYPERTROPHY; PULMONARY-HYPERTENSION; MYOCARDIAL-INFARCTION; ACE-INHIBITION; RATS; DYSFUNCTION; BAY-41-2272; FAILURE; STIMULATION; chronic renal failure; progression; HMR1766; guanylyl cyclase activator; nitric oxide |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Jan 2021 09:26 |
| Last Modified: | 13 Jan 2021 09:26 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33468 |
Actions (login required)
 |
View Item |
